A real life study to determine clinical characteristics and outcomes of non-small cell lung cancer patients with RET rearrangements who received systemic treatments
Latest Information Update: 29 Jul 2020
At a glance
- Drugs Pemetrexed (Primary) ; Vandetanib (Primary) ; Immunotherapies
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 29 Jul 2020 New trial record